Navigation Links
Karkus Nominees Caution Quigley Shareholders Not to be Fooled by the Company's Latest Announcement
Date:5/19/2009

WOODMERE, N.Y., May 19 /PRNewswire/ -- The Quigley Corporation (Nasdaq: QGLY) announced yesterday that its Board was exploring various options, including hiring an investment banker and exploring "strategic alternatives".

Ted Karkus, Mark Burnett, John DeShazo, Mark Frank, Louis Gleckel, MD, Mark Leventhal, and James McCubbin ("the Shareholder Nominees") believe that the recent announcement is an 11th hour attempt to obtain shareholder votes and is further evidence of the need for a slate of new highly qualified directors to protect the interests of all shareholders.

"Shareholders should ask why the incumbents released this announcement just two days before the shareholder meeting," commented Mr. Karkus. "A responsible Board should always be reviewing the Company's strategic alternatives," he added.

Ask yourself if you want the same Board that managed the Darius/Innerlight sale last year to execute any further "strategic alternatives". The Darius/Innerlight division was sold for a mere $1 million just before it turned around in early 2008. Please read our last press release which summarizes some of the many facts that trouble us with that transaction.

And, finally, ask yourself why they didn't pursue these "strategic alternatives" when the Company's OTC division had increasing sales and increasing profits, instead of now, when the division is likely to be worth significantly less, given declining sales, increasing losses and a weaker environment for selling assets.

For more information on the actions by Quigley management that have necessitated this proxy contest and the Federal Court's decision to reject Quigley's claims against the Shareholder Nominees, shareholders should refer to our previous press releases and the court order which are available at

SOURCE Ted Karkus
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. The Quigley Corporation Issues Open Letter to Stockholders; Urges Stockholders to Reject Dissident Ted Karkus Solicitation Efforts
2. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
3. Judge Rejects Quigleys Claims - Karkus Director Candidates Prevail in Federal Court
4. Lab Series(R) Skincare For Men Spa Indulges the 2007 Primetime Emmy(R) Nominees at the Sofitel(R) Los Angeles
5. Erie Indemnity Announces Nominees for Board of Directors
6. LCA-Vision Announces Termination of Consent Solicitation and Withdrawal of Dissident Slate of Director Nominees
7. Tennenbaum Encourages Shareholders to Vote the Blue Proxy for Tennenbaum Director Nominees at Online Resources Annual Meeting as Recommended by Riskmetrics/ISS and Proxy Governance
8. MMI Investments Issues Letter to Chemed Stockholders Illustrating the Superior Qualifications of the MMI Nominees
9. Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital
10. Americans United for Life Announces Legal Prospectus on Probable Supreme Court Nominees
11. Support Bristols Highly Qualified Independent Nominees for Advocat Board
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 2Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 3Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 4Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3Reminder Program Dramatically Increases Mammography Rates Kaiser Permanente Study Finds 51572 1Reminder Program Dramatically Increases Mammography Rates Kaiser Permanente Study Finds 51572 2Reminder Program Dramatically Increases Mammography Rates Kaiser Permanente Study Finds 51572 3Reminder Program Dramatically Increases Mammography Rates Kaiser Permanente Study Finds 51572 4Brazil proves developing countries can use generic medicines to fight HIV AIDS epidemic 51571 1Brazil proves developing countries can use generic medicines to fight HIV AIDS epidemic 51571 2Brazil proves developing countries can use generic medicines to fight HIV AIDS epidemic 51571 3Eliminating polio requires global coordinated effort Health Affairs article highlights risks rewards of eradication 51569 1Eliminating polio requires global coordinated effort Health Affairs article highlights risks rewards of eradication 51569 2Eliminating polio requires global coordinated effort Health Affairs article highlights risks rewards of eradication 51569 3Eliminating polio requires global coordinated effort Health Affairs article highlights risks rewards of eradication 51569 4Eliminating polio requires global coordinated effort Health Affairs article highlights risks rewards of eradication 51569 5